The Medicines Company has filed lawsuits in the US District Court against Teva Parenteral Medicines, PLIVA Hrvatska and related entities over alleged patent infringement over a generic version of the company’s anti-clotting agent Angiomax.

The company is alleging patent infringement based on Abbreviated New Drug Applications seeking US Food and Drug Administration approval to market and sell generic versions of Angiomax prior to expiration of the 343 patent.

Angiomax is an anticoagulant approved in the US for use in patients undergoing percutaneous coronary intervention, and in patients with or at risk of heparin-induced thrombocytopenia and thrombosis syndrome.